Dose Escalation of Blinatumomab is a Better Option for MRD-Positive CR Patients, Results from a Single-Center Real World Study of Blinatumomab for B-Cell Acute Lymphoblastic Leukemia in China
BLOOD（2023）
Key words
Treatment Outcomes
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined